Lamifiban

Drug Profile

Lamifiban

Alternative Names: Lamstat™; RO 449883

Latest Information Update: 14 Apr 2000

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Roche
  • Class Acetates; Antiplatelets; Aromatic amino acids; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Myocardial infarction; Unstable angina pectoris

Most Recent Events

  • 14 Apr 2000 Discontinued-II for Unstable angina pectoris in Japan (IV)
  • 14 Apr 2000 Discontinued-III for Myocardial infarction in World (IV)
  • 14 Apr 2000 Discontinued-III for Unstable angina pectoris in World (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top